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Abstract. Synchronous or metachronous malignancies are a 
rare event, with an incidence rate that increases with age. The 
present study reports the case of a 70-year-old Caucasian male 
who was referred to the outpatient office of the Urology Unit, 
Sapienza University of Rome (Latina, Italy) due to lower 
urinary tract symptoms. An abdominal ultrasound 
investigation was performed that demonstrated the presence of 
a right renal mass. The patient underwent right radical 
nephrectomy, which resulted in the definitive diagnosis of 
clear cell type renal cell carcinoma. The patient was eventually 
diagnosed with triple primary metachronous cancer consisting 
of renal clear cell carcinoma, prostate adenocarcinoma and 
squamous cell carcinoma of the oropharynx (palatine tonsil). 
To the best of our knowledge, this combination of primary 
neoplasms has not previously been documented. 
Introduction 
Multiple primary malignant tumors (MPMTs) are rarely 
observed in clinical practice, however, certain fundamental 
factors for the potential etiology have been described in the 
literature, including the environment and behavior (tobacco, 
occupation, pollution and ultraviolet light), genetic 
predisposition (Li‑ Fraumeni or Beckwith‑ Wiedemann 
syndromes), previous medical treatment (radiotherapy or 
chemotherapy) and complex interaction between all these 
factors (1). The association between varying cancer types can 
be classified into two categories, which are dependent on the 
timing of their discovery. An American review stated that the 
tumors are synchronous when the cancers occur at the same 
time or within 2 months of each other, whereas metachronous  
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tumors occur when the cancers follow in sequence more than 
2 months apart (2). The most widely accepted definition is that 
described by Moertel, which stated that synchronous 
neoplasms may be defined as ≥2 primary neoplasms that are 
diagnosed within 6 months of each other, while metachronous 
neoplasms may be defined as those detected following an 
interval of >6 months (3). These definitions are all based on 
the time that the neoplasms are discovered rather than on the 
onset of disease. MPMT was documented for the first time in 
a single patient in a study by Billroth in 1889 (4). The majority 
of MPMTs that occur in multiple organs are metachronous, 
while the presence of synchronous lesions is less common, and 
in accordance with the behavior of malignancy lesions, these 
tumors are more frequent with aging. Ray et al reported that 
13.5% of patients with multiple primary malignancies have 
genitourinary tumors (5). The current study presents the case 
of a patient who developed primary right renal cell carcinoma 
(RCC), and metachronous prostate and left palatine tonsil 
neoplasms. To the best of our knowledge, this combination of 
primary tumors has not previously been reported. 
Case report 
A 70‑ year‑ old male ex‑ smoker (20 to 30 cigarettes per day 
from the age of 20 years old) was referred to the outpatient 
office of the Urology Unit, Sapienza University of Rome 
(Latina, Italy) with lower urinary tract symptoms due to benign 
prostatic enlargement. The laboratory investigations were 
within normal limits, with a prostate‑ specific antigen (PSA) 
level of 3.91 ng/ml (normal range: 0-4 ng/ml). The digital 
rectal examination (DRE) was negative. The medical history 
revealed high blood pressure and diabetes. The family history 
was negative for malignancies. The ultrasound examination of 
the urogenital system revealed nodular hyperplasia of the 
prostate and a right renal mass. A full-body computed 
tomography (CT) scan was performed for staging of the 
disease and showed a lesion with irregular contours in the 
superior pole of the right kidney. The largest diameter of the 
tumor was 11.5 cm. The CT scan also revealed 
lymphadenopathy in the context of the hepatogastric ligament, 
coeliac artery and interaortocaval region. The patient 
underwent right a radical nephrectomy to remove the lesion, 
with a wedge resection. Pathological examination showed 
renal parenchyma infiltrate by the proliferation  
 
Figure 2. Low‑ power photomicrograph showing epithelial neoplasia, with 
ulcerated and infiltrating subepithelial connective and lymphoid tonsillar 
tissue, consisting of squamous cells arranged in solid nests, composed of cells 
with polymorphic nuclei, occassionally with evident nucleoli and large 
eosinophilic cytoplasm, with ill‑ defined limits (magnification, x4). 
of medium-large size cells with slightly irregular nuclei, with 
the nucleoli easily visible, clear cytoplasm and distinct cell 
membranes, organized in nest structures; the diagnosis was 
renal cell carcinoma, clear cell type, nuclear Furhman grade 2, 
with involvement of the renal vein and perinephric fat (Fig. 1A 
and B). The tumor pathological stage according to the 
American Cancer Committee Union for International Cancer 
Control (2009) was pT2b (6).  
At ~7 months after the kidney surgery, positron emission 
tomography using 2-[18F]fluoro‑ 2‑ deoxy‑ D‑ glucose, in 
combination with CT, demonstrated a pathological cancer 
focus in the left palatine tonsil. During a routine follow‑ up 
examination, a serum PSA level of 5.93 ng/ml was detected.  
DRE was negative again and finally, a transperineal 
ultrasound-guided sextant biopsy of the prostate was 
performed. Histological examination of the tonsillar tissue 
revealed a poorly‑ differentiated (G3) squamous cell 
carcinoma (Fig. 1C and D).A histological examination of the 
prostatic needle core biopsies showed a proliferation of 
small/medium size glands, often fused, composed of cellular 
elements with hyperchromatic nuclei, with evident nucleolus, 
and slightly eosinophilic cytoplasm. The diagnosis was 
adenocarcinoma of the prostate, Gleason score 8 (4+4) (Fig. 
1C and D). The patient began a treatment program with 
external beam radiotherapy (EBR; 70 Gy in 1.8 to 2.0 Gy 
fractions) and concurrent chemotherapy with carboplatin 
(target AUC 2 on days 1, 8 and 15 for 6 cycles every 28 days) 
for the palatine tonsil squamous tumor. Furthermore, at the end 
of the tonsil cancer treatment, the patient is scheduled to start 
prostate EBR and hormonal therapy with a luteinizing 
hormone-releasing hormone agonist. The patient provided 
written informed consent for publication of this case report. 
Discussion 
The incidence of MPMT is estimated to be between 0.73 and 
11.7% (7). In order to establish a definitive diagnosis of 
multiple neoplasms, the criteria described by Warren and 
Gates in 1932 must be adhered to (8). Each of the tumors must 
present a definite picture of malignancy and each one must be 
distinct from the other; the probability of one tumor being a 
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Figure 1. (A) Low‑ power photomicrograph showing a solid renal neoplasia composed of nests of cellular elements with distinct cell membranes and optically 
clear cytoplasm (magnification, x4). (B) High‑ power photomicrograph showing cells of a medium‑ large size with slightly irregular nuclei and easily visible 
nucleoli (magnification, x40). (C) Low‑ power photomicrograph showing a prostatic needle core biopsy with an area of neoplastic proliferation (magnification, 
x4). (D) High‑ power photomicrograph showing a proliferation of small/medium size glands, often fused, composed of cellular elements with hyperchromatic 
nuclei, evident nucleoli and slightly eosinophilic cytoplasm (magnification, x40). 
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metastasis of the other must excluded (8). The present case met 
the criteria set by Warren and Gates. The study reported a 
patient who developed three distinct malignancies, all of 
which originated from epithelial elements; the RCC, and 
metachronous prostate and left palatine tonsil neoplasms 
occurred within a period of <1 year. There were no 
predisposing factors for these tumors, with the exception that 
the patient was a heavy smoker.  
RCCs account for 90‑ 95% of malignant neoplasms arising 
from the kidney (9). The Fuhrman histological classification 
system is the most widely accepted for grading tumors. 
Identified etiological factors are mainly associated with 
lifestyle, such as smoking status, obesity and hypertension, 
however, the majority of patients do not present with any 
specific symptoms (9). A variety of factors, including tumor 
size and location, local or distant spread, renal function, 
comorbidities and performance status, must be considered 
when assessing the treatment for RCC (9).  
Prostate cancer is the most common neoplasm in European 
men, particularly elderly men (10). In fact, 15% of male 
cancers are prostate cancers in developed countries. Three 
well-established risk factors are associated with prostate 
cancer, namely, increasing age, ethnic origin and heredity. The 
Gleason score is the recommended methodology for grading 
prostate cancer (10). Diagnostic techniques for prostate cancer 
include DRE, analysis of serum PSA concentration and 
transrectal ultrasound-guided biopsy. The diagnosis of prostate 
cancer is based on the histological examination. The choice of 
treatment depends primarily on the characteristics of the 
patient and the stage of disease, and will vary for patients with 
low‑ , intermediate‑  and high‑ risk prostate cancer (10).  
Squamous cell carcinoma of the head and neck is classified 
based on the following affected regions: Oral cavity, 
oropharynx, nasopharynx, hypopharynx and larynx, with the 
tonsils considered to be a subsite of the oropharynx (11). There 
is a strict association between this tumor and tobacco use and 
alcohol consumption. Squamous cell carcinoma of the 
oropharynx exhibits non‑ specific symptoms and the rich 
lymphatic drainage of the tonsils is believed to promote early 
spread (11). The diagnosis of tonsil palatine cancer is based on 
histological examination. Treatment of the head and neck 
cancer can consist mainly of radiation therapy, surgery or 
surgery with radiation therapy as an adjunctive treatment (11). 
The incidence of MPMT is currently rising due to 
improved diagnostic modalities and therapeutic protocols, 
which result in a greater number of patients with cancer 
surviving long enough to develop a second cancer. The 
incidence of cancer, including MPMT, increases with age (12). 
With improvements in the survival rates and the aging of the 
population, the frequency of individuals with multiple cancers 
will increase in the future. Warren and Gates (8) stated that the 
occurrence of a first malignancy is a risk for a second 
malignancy in that individual; in fact, the first neoplasm was 
likely initiated by factors and agents that may initiate a second 
neoplasm as well. Luciani and Balducci (12) recognized two 
etiological hypotheses for MPMT: The inheritance of 
predisposing genomic defects and field carcinogenesis. The 
first theory concerns certain germ‑ line mutations that may 
result in malignancies in multiple organ systems (such as 
xeroderma pigmentosum) or in malignancies confined to one 
organ system (such as familial polyposis coli). The second 
theory supports the hypothesis that those organ systems with 
neoplasms are likely to develop multiple and independent 
neoplasms, as all cells have been exposed to the same dose of 
carcinogens for the same time. The concept of field 
carcinogenesis can justify the association of aging and multiple 
malignancies: The longer a person lives, the greater the risk of 
developing tumors (12). Luciani and Balducci concluded that 
the incidence of MPMT increases with the age; this increment 
does not appear be caused by an aging phenotype, but rather it 
represents a random event (12).  
In a study on 1,425 patients with RCC, Beisland et al (13) 
found that 16% presented with only 1 tumor, 1.6% presented 
with 2 tumors and 0.2% presented with 3 other primary 
malignancies. On average, 46.7% of tumors occurred as 
metachronous tumors. The most common second malignancy 
was prostatic cancer. This is in agreement with the order of 
occurrence in the present patient. In the study by Beisland et 
al (13), the cumulative risk of developing second primary 
malignancy was found to be as high as 26.6% in males with 
RCC. Therefore, it was concluded that patients with RCC have 
a significantly higher risk of developing further primary 
malignancies. Genetic, environmental and dietary factors, as 
well as obesity, were indicated to be etiological factors for the 
development of cancer of the prostate, breast, kidney and colon 
(13). In our previous studies, two cases of urinary tract 
synchronous involvement from other malignancies were 
described. The first study reported a case of synchronous 
primary tumors (bladder, breast and skin) in a male patient (14), 
and the second reported a case of synchronous ureteral and 
bladder metastases from invasive ductal breast carcinoma in an 
elderly female (15). 
The present case highlights the fact that synchronous or 
metachronous malignancies should be considered in cases 
where a new tumor appears in a previous cancerous patient. 
Since an association between RCC and other malignancies has 
been shown in the literature, the present study poses the 
question as to whether patients with renal cell carcinoma can 
have an increased risk of subsequent second primary 
malignancy. To the best of our knowledge, this is the first 
reported case in the literature of this combination of primary 
neoplasms. 
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